Current version snapshot
Current · version 4: Lixisenatide↗
Related names recorded in this version: Soliqua 100/33, Adlyxin↗↗↗
A GLP-1 receptor agonist approved by FDA as Adlyxin, and in combination with insulin glargine as Soliqua 100/33, to improve blood-sugar control in adults with type 2 diabetes.↗↗↗
The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers drawn from the Adlyxin and Soliqua 100/33 labels, and added the Drugs@FDA approval record for Adlyxin. 213
What this version reported
Large randomized trials described in the labels support these uses. In the ELIXA trial of 6,068 adults after a recent acute coronary syndrome, the results ruled out a prespecified increase in major cardiovascular risk compared with placebo.↗↗
Reader guide in this version
Key takeaway
Lixisenatide is a GLP-1 receptor agonist, a peptide that acts like a gut hormone involved in blood-sugar control. Drugs@FDA lists it as the active ingredient of Sanofi’s Adlyxin, first approved on July 27, 2016.2,3 It is FDA-approved, with diet and exercise, to improve blood-sugar control in adults with type 2 diabetes, both on its own as Adlyxin and combined with insulin glargine as Soliqua 100/33.1,2 In ELIXA, a randomized trial of 6,068 adults with type 2 diabetes after a recent heart attack or unstable angina, the results ruled out a prespecified increase in major cardiovascular risk compared with placebo.2
At a glance
- What it is
- A GLP-1 receptor agonist. The Adlyxin label states that it increases insulin release when blood sugar is high, decreases glucagon release and slows stomach emptying.2
- FDA status
- FDA-approved. Drugs@FDA lists Adlyxin with an original approval date of July 27, 2016; lixisenatide is also a component of Soliqua 100/33. Neither cited label has a boxed warning.1,2,3
- Human evidence
- Large randomized trials described in the labels, including the ELIXA cardiovascular safety trial and two trials of the insulin glargine combination.1,2
- Evidence strength
- Large randomized human trials
What is lixisenatide?
Lixisenatide is a lab-made peptide that the Adlyxin label describes as a GLP-1 receptor agonist.2
Drugs@FDA lists it as the active ingredient of Adlyxin, from Sanofi. The Soliqua 100/33 label describes a combination of insulin glargine and lixisenatide.1,3
How does lixisenatide work?
The Adlyxin label states that lixisenatide increases insulin release when blood sugar is high, decreases glucagon release and slows stomach emptying.2
The label reports that its effect on blood sugar after meals was most notable after the first meal of the day and weaker after later meals.2
What do human studies show?
In ELIXA, described in the Adlyxin label, 6,068 adults with type 2 diabetes and a recent acute coronary syndrome were randomized to lixisenatide or placebo and followed for a median of about 26 months.2
The hazard ratio for the main outcome, a composite of cardiovascular death, heart attack, stroke or hospitalization for unstable angina, was 1.02, and the label states that the upper limit of its confidence interval, 1.17, excluded the prespecified risk margin of 1.3. The trial was designed to rule out increased risk, not to show a reduction.2
The Soliqua 100/33 label describes two 30-week randomized trials in 1,170 and 736 adults with type 2 diabetes, in which the combination produced statistically significant improvements in HbA1c, a measure of long-term blood sugar, compared with the active comparators.1
What the evidence base contains
- Large randomized human trial ELIXA: a randomized, double-blind, placebo-controlled trial in 6,068 adults with type 2 diabetes after a recent acute coronary syndrome, designed to rule out an increase in cardiovascular risk.2
- Large randomized human trial Two 30-week randomized, active-controlled trials of Soliqua 100/33 in 1,170 and 736 adults with type 2 diabetes (NCT05058147 and NCT02058160).1
Evidence-strength label: Large randomized human trials. How this label is assigned
Is lixisenatide FDA-approved?
Yes. Drugs@FDA lists Adlyxin, application BLA208471, with an original approval date of July 27, 2016.3
The Adlyxin prescribing information cited here (revised November 2024) states that it is indicated, with diet and exercise, to improve blood-sugar control in adults with type 2 diabetes, that it should not be used in type 1 diabetes, and that it is not recommended in people with gastroparesis.2
The Soliqua 100/33 label cited here (DailyMed SPL version 25, published March 20, 2026) states that the combination of insulin glargine and lixisenatide is indicated, with diet and exercise, to improve blood-sugar control in adults with type 2 diabetes.1
Neither label has a boxed warning. The Adlyxin label states that it is contraindicated in people with severe allergic reactions to it, and its warnings cover anaphylaxis, acute pancreatitis, low blood sugar with insulin or insulin secretagogues, acute kidney injury, antibodies, gallbladder disease and aspiration during anesthesia or deep sedation.2
What is still unknown?
Whether lixisenatide reduces cardiovascular events: ELIXA was designed to rule out increased risk, not to show benefit.2
Its effects in people with a history of pancreatitis or with gastroparesis, in whom the Adlyxin label says it has not been studied.2
Sources for this version
- 1SOLIQUA 100/33 (insulin glargine and lixisenatide) injection · SPL version 25 · published 2026-03-20 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2ADLYXIN, revised November 2024: U.S. prescribing information ↗
U.S. Food and Drug Administration · Official source · Source checked September 15, 2026
- 3Drugs@FDA application BLA208471 · original submission status AP · 2016-07-27 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026